Alkermes (ALKS) Selling, General & Administrative (2010 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Selling, General & Administrative (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.17 Bn | 624.41 Bn | 17.26 Bn | 6.43 Bn |
| 2 | AbbVie | 440.86 Bn | 434.29 Bn | 12.70 Bn | 3.63 Bn |
| 3 | Merck | 364.81 Bn | 357.67 Bn | 12.21 Bn | 2.90 Bn |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn | -3.24 Bn |
| 5 | Pfizer | 158.95 Bn | 147.25 Bn | 10.94 Bn | 3.41 Bn |
| 6 | Sanofi | 52.53 Bn | 45.15 Bn | 10.79 Bn | -2.87 Bn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | 110.21 Mn |
| 8 | Incyte | 25.27 Bn | 20.73 Bn | 1.57 Bn | 351.74 Mn |
| 9 | United Therapeutics | 21.40 Bn | 18.74 Bn | 683.80 Mn | 206.70 Mn |
| 10 | Alkermes | 7.57 Bn | 6.92 Bn | 397.90 Mn | 217.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 217.63 Mn |
| Mar 31, 2026 | 264.59 Mn |
| Dec 31, 2025 | 187.20 Mn |
| Sep 30, 2025 | 171.77 Mn |
| Jun 30, 2025 | 170.85 Mn |
| Mar 31, 2025 | 171.70 Mn |
| Dec 31, 2024 | 146.99 Mn |
| Sep 30, 2024 | 150.38 Mn |
| Jun 30, 2024 | 168.11 Mn |
| Mar 31, 2024 | 179.75 Mn |
| Dec 31, 2023 | 169.79 Mn |
| Sep 30, 2023 | 156.37 Mn |
| Jun 30, 2023 | 195.76 Mn |
| Mar 31, 2023 | 167.83 Mn |
| Dec 31, 2022 | 142.55 Mn |
| Sep 30, 2022 | 152.78 Mn |
| Jun 30, 2022 | 150.38 Mn |
| Mar 31, 2022 | 145.05 Mn |
| Dec 31, 2021 | 149.04 Mn |
| Sep 30, 2021 | 136.21 Mn |